Arnaud Carpentier
About
Arnaud Carpentier is from Hannover, Lower Saxony, Germany. Arnaud works in the following industries: "Research Services". Arnaud is currently Research Scientist at Twincore, Center for Experimental and Clinical Infection Research, located in Hannover, Germany. In Arnaud's previous role as a Post Doctoral Fellow at National Institutes of Health - NIDDK, Arnaud worked in Bethesda, MD until Sep 2015. Prior to joining National Institutes of Health - NIDDK, Arnaud was a TRAC CRM49 : Making iPSC From Blood – Summer 2013 at Biotechnology Training Courses (BIO-TRAC) - National Institutes of Health and held the position of TRAC CRM49 : Making iPSC From Blood – Summer 2013 at Bethesda, MD. Prior to that, Arnaud was a PhD Student at INSERM - Institut Cochin, based in Paris, France from Jan 2006 to Aug 2010. Arnaud started working as Master Student at CNRS - Institut de Biologie de Lille (IBL) in Lille, France in Jul 2003.
If you’re looking for Arnaud Carpentier's email address, you can find it on finalscout.com. Finalscout is a professional database with more than 500 million business professionals and 200 million company profiles.
Arnaud Carpentier's current jobs
Institute for Experimental Virology. Main publication: Carpentier A, Sheldon J, Vondran FWR, et al. Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus, Gut Published Online First: 29 February 2020. doi: 10.1136/gutjnl-2019-319354
Arnaud Carpentier's past jobs
As a post doctoral fellow in the Liver Diseases Branch (NIH/ NIDDK; mentor: Dr T Jake Liang), I was in charge of developing a platform of differentiation of human pluripotent stem cells (Induced and embryonic) into functional hepatocytes. We demonstrated that these differentiated hepatocytes are permissive to Hepatitis C Virus (HCV) infection in vitro. We also performed in vivo engraftment of differentiated hepatocytes into the liver of chimeric mice, and demonstrated for the first time that engrafted human stem cell-derived hepatocytes proliferate, maturate and are permissive to HCV infection in vivo. This model constitutes a unique tool to analyze long-term infection by the Hepatitis C Virus (HCV) in the context of the patient genetic background. Finally, we also worked on optimizing hepatic differentiation protocols. We described the first protocol allowing consistent and efficient hepatic differentiation in 384 well plates. This protocol opens the way for using patients-derived differentiated cells for high throughput screening. Main publication: Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model Carpentier A, Tesfaye A, Chu V, Nimgaonkar I, Zhang F, Lee SB, Thorgeirsson SS, Feinstone SM and Liang TJ. Journal of Clinical Investigation, 2014;124(11):4953–4964.
Teaching experience: Hepatic differentiation of human pluripotent stem cells
During my Ph.D., I worked on the design of an in vitro model of infection of Primary Human adult Hepatocytes (PHHs) by the Hepatitis C Virus (HCV), a more relevant model than the currently used model based on subclones of the transformed Huh7 cell line. We demonstrated that PHHs can be infected by HCV in vitro and allow production of viral particles presenting the same characteristics as the virions found in the blood of patients (High specific infectivity associated with low buoyant density). Main publication: Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Podevin P*, Carpentier A*, Pène V, Aoudjehane L, Carrière M, Zaïdi S, Hernandez C, Calle V, Méritet JF, Scatton O, Dreux M, Cosset FL, Wakita T, Bartenschlager R, Demignot S, Conti F, Rosenberg AR, Calmus Y. Gastroenterology. 2010 Oct;139(4):1355-64. * Co first-authors
During my 2 years as a summer student and then Master student at the Institut de Biologie de Lille (CNRS, Lille, France), I worked on the role of regulatory T cells (Tregs) during the recurrence of Hepatitis C after liver transplantation. We demonstrated that a particular subset of Tregs, called IL-10 secreting Tr1s, were associated with a faster and more severe recurrence of the infection. Main publication: Increased expression of regulatory Tr1 cells in recurrent hepatitis C after liver transplantation. Carpentier A, Conti F, Stenard F, Aoudjehane L, Miroux C, Podevin P, Morales O, Chouzenoux S, Scatton O, Groux H, Auriault C, Calmus Y, Pancre V, Delhem N. Am J Transplant. 2009 Sep;9(9):2102-12.